MIT-based Spinoff Sigilon Therapeutics Raises $80.3m Series B to Advance “Shielded Living Therapeutics” to Clinical Trials

Sigilon Therapeutics, Inc., a biotechnology company developing cures for patients with chronic diseases through its Shielded Living Therapeutics Platform, announced it completed a $80.3 million Series B financing. This money will be put to use supporting the...

Novo Nordisk Enters into Agreement with Bluebird Bio, a Company Currently in Litigation with Errant Gene Therapeutics

Novo Nordisk and Bluebird Bio., previously known as Genetix and purchased by Third Rock Ventures, will collaborate to develop genome editing treatments for genetic diseases, citing specifically the bleeding disease hemophilia as a target disorder, noted Jonathan...

Pin It on Pinterest